photoreceptor layer, but also bipolar and other cells in the in- ner retina. Also, the amplitude and implicit time can be influ- enced by injury or atrophy of the retina, particularly of the photoreceptor layer and retinal pigment epithelium. Such in- juries may alter retinal function, which cannot be measured by changes of visual acuity and anatomy. Therefore, measuring only visual acuity or anatomical changes might miss information regarding retinal function that might be observed if the ob- jective parameter was included. Evaluation with retinal func- tion can offer more comprehensive information in order to make detailed assessments of effective treatment. In conclusion, intravitreal bevacizumab injection improved patients’ visual acuity and caused anatomical changes in CNV secondary to AMD. Furthermore, intravitreal injection of bevacizumab resulted in improvement of mfERG responses, especially the implicit time compared with amplitude. There is a potential role for mfERG in assessing the functional changes of the central retina after intravitreal bevacizumab injection. To better evaluate objective changes of retinal functions using mfERG after intravitreal bevacizumab injection, fur- ther prospective randomized controlled clinical trials will be needed, with scheduled re-injections and longer follow-up intervals. Conflict of Interest No potential conflict of interest relevant to this article was reported. References 1. Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72. 2. Kroll P, Meyer CH. Which treatment is best for which AMD patient? Br J Ophthalmol 2006;90:128-30. 3. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25: 111-8. 4. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. 5. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009;29:1062-6. 6. Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009;29:319- 24. 7. Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126:782-90. 8. Schouten JS, La Heij EC, Webers CA, et al. A systematic re- view on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11. 9. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bev- acizumab (Avastin) for neovascular age-related macular JY Park, et al. MfERG after Intravitreal Bevacizumab Injection degeneration. Ophthalmology 2006;113:363-372.e5. 10. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neo- vascular age-related macular degeneration. Retina 2006;26:495- 511. 11. Kim YH, Kim ES, Yu SY, Kwak HW. Long-term effect of in- travitreal bevacizumab for CNV secondary to age-related macular degeneration. J Korean Ophthalmol Soc 2008;49:1935-40. 12. Karanjia R, Eng KT, Gale J, et al. Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exu- dative age-related macular degeneration. Br J Ophthalmol 2008;92:1248-52. 13. Moschos MM, Brouzas D, Apostolopoulos M, et al. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 2007;114:37-44. 14. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic find- ings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-4. 15. Berrow EJ, Bartlett HE, Eperjesi F, Gibson JM. The electro- retinogram: a useful tool for evaluating age-related macular disease? Doc Ophthalmol 2010;121:51-62. 16. Oh SB, Cho WB, Moon JW, Kim HC. Effects and prognostic factors of intravitreal bevacizumab injection on choroidal neo- vascularization from age-related macular degeneration. J Korean Ophthalmol Soc 2009;50:202-10. 17. Maturi RK, Yu M. Multifocal electroretinography and its clin- ical application. In: Ciulla TA, Regillo CD, Harris A, editors. Retina and optic nerve imaging. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 213-30. 18. Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal ori- gins of the primate multifocal ERG: implications for the hu- man response. Invest Ophthalmol Vis Sci 2002;43:1673-85. 19. Hood DC. Assessing retinal function with the multifocal technique. Prog Retin Eye Res 2000;19:607-46. 20. Marmor MF, Tan F, Sutter EE, Bearse MA Jr. Topography of cone electrophysiology in the enhanced S cone syndrome. Invest Ophthalmol Vis Sci 1999;40:1866-73. 21. Kretschmann U, Stilling R, Rüther K, Zrenner E. Familial macular cone dystrophy: diagnostic value of multifocal ERG and two-color threshold perimetry. Graefes Arch Clin Exp Ophthalmol 1999;237:429-32. 22. Li J, Tso MO, Lam TT. Reduced amplitude and delayed la- tency in foveal response of multifocal electroretinogram in early age related macular degeneration. Br J Ophthalmol 2001;85:287-90. 23. Kondo M, Miyake Y, Horiguchi M, et al. Clinical evaluation of multifocal electroretinogram. Invest Ophthalmol Vis Sci 1995;36:2146-50. 24. Schneck ME, Bearse MA Jr, Han Y, et al. Comparison of mfERG waveform components and implicit time measure- ment techniques for detecting functional change in early dia- betic eye disease. Doc Ophthalmol 2004;108:223-30. 25. Hood DC, Holopigian K, Greenstein V, et al. Assessment of local retinal function in patients with retinitis pigmentosa us- ing the multi-focal ERG technique. Vision Res 1998;38:163-79. 26. Seeliger M, Kretschmann U, Apfelstedt-Sylla E, et al. Multifocal electroretinography in retinitis pigmentosa. Am J Ophthalmol 1998;125:214-26. 27. Miyake Y, Horiguchi M, Tomita N, et al. Occult macular dystrophy. Am J Ophthalmol 1996;122:644-53. 28. Hood DC, Odel JG, Chen CS, Winn BJ. The multifocal electroretinogram. J Neuroophthalmol 2003;23:225-35. 165